ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

ViiV Healthcare today announced new collaborations with the goal of increasing access to its HIV medicine, dolutegravir (marketed under the name Tivicay®), just two months after its approval by the European Medicines Agency (EMA) and eight months after approval by the US Food and Drug Administration (FDA).
Source: GSK news - Category: Pharmaceuticals Source Type: news